title: ST resolution in a single electrocardiographic lead: a simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction.
abstract: BACKGROUND
  The extent of ST-segment resolution in the 12-lead electrocardiograph (ECG) obtained early after reperfusion therapy in patients with ST-elevation myocardial infarction (MI) has been shown to predict short- and long-term mortalities. To improve the ease of this method in clinical practice, we sought to evaluate the optimal cutoffs and the prognostic value of ST resolution (STR) measured in a single ECG lead.
  
  
  METHODS
  In conjunction with the Intravenous nPA for the Treatment of Infarcting Myocardium Early (InTIME)-2 study, in which patients with an ST-elevation MI of <6 hours' duration were treated with alteplase or lanoteplase, 12-lead ECGs were obtained at baseline and 90 minutes after the start of fibrinolytic therapy in 3030 patients.
  
  
  RESULTS
  There was a close correlation between the extent of the sum STR and single-lead ST-elevation resolution ( r = 0.94). The optimal cutoffs for definition of single-lead complete, partial, and no-STR groups were 70% and 50% for anterior infarcts and 70% and 20% for inferior infarcts. The cardiac 30-day mortality rates for the 2 sets of risk groups by sum or single-lead STR were as follows: no resolution, 9.5% vs 10.3%; partial resolution, 5.0% vs 3.6%; complete resolution, 2.0% vs 1.2%. The predictive power was significantly better for single-lead STR.
  
  
  CONCLUSIONS
  ST resolution obtained in a single lead is an easy and accurate prognosticator of cardiac 30-day mortality in patients with ST-elevation MI. It is therefore useful for early identification of low- and high-risk subgroups after fibrinolysis and as a surrogate end point in clinical trials.
authors.affiliation: Medizinische Klinik B, Herzzentrum Ludwigshafen, Ludwigshafen, Germany. uwe.zeymer@t-online.de
authors.forename: Uwe
authors.initials: U
authors.lastname: Zeymer
authors.forename: Klaus
authors.initials: K
authors.lastname: Schröder
authors.forename: Karl
authors.initials: K
authors.lastname: Wegscheider
authors.forename: Jochen
authors.initials: J
authors.lastname: Senges
authors.forename: Karl-Ludwig
authors.initials: KL
authors.lastname: Neuhaus
authors.forename: Rolf
authors.initials: R
authors.lastname: Schröder
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality*; D011379:Prognosis; D012372:ROC Curve; D018570:Risk Assessment; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; C081981:lanoteplase; D010959:Tissue Plasminogen Activator